Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial
Key facts
- Who runs it
- Dow University of Health Sciences
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 120 people enrolled
- Started
- 6 Apr 2025
- Ended
- 5 Jan 2026
- Type of study
- Interventional, 3 groups
- Treatments tested
- ruxolitinib cream
- Record updated
- 26 January 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- adult aged 18 to 65 years male or female patients non-segmental vitiligo vitiligo involving less then 10% body surface area willingness to provide written informed consent
Who cannot take part
- pregnant or lactating females known hypersentivity to ruxolitinib, tacrolimus or topical corticosteriods current use of systemic immunosuppressive therapy use of biologic therapy or phototherapy within the previous 12 weeks
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
this randomized controlled trial aims to compare the effectiveness and safety of ruxolitinib monotherapy versus its combination with topical tacrolimus or topical corticosteroids in patients with non-segmental vitiligo involving less than 10% body surface area. A total of 120 adult patients will be randomized into three treatment groups and followed for 24 weeks. Treatment response will be evaluated using validated scoring systems including the Vitiligo Area Severity Index (VASI), Vitiligo European Task Force (VETF) staging, and Physician Global Assessment. The findings may help optimize topical treatment strategies for vitiligo.
The 3 groups in the trial
- group aOther group
ruxolitinib monotherapy
Treatment: ruxolitinib cream
- group bOther group
ruxolitinib with tacrolimus
Treatment: ruxolitinib cream
- group cOther group
ruxolitinib with corticosteriods
Treatment: ruxolitinib cream
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 26 January 2026